Lactic acid (DrugBank: Lactic acid)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 3 |
| 299 | Cystic fibrosis | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00126308 (ClinicalTrials.gov) | November 2005 | 1/8/2005 | Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy | A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH) | HIV-Associated Lipodystrophy;HIV Infections | Device: poly-L-lactic acid | Kirby Institute | The University of New South Wales;Abbott;Bristol-Myers Squibb;Gilead Sciences;GlaxoSmithKline;Merck Sharp & Dohme Corp.;Hoffmann-La Roche;AIDS Council of New South Wales | Terminated | 18 Years | N/A | Both | 100 | Phase 4 | Australia |
| 2 | NCT00202228 (ClinicalTrials.gov) | July 2002 | 13/9/2005 | Lactate Metabolism Study in HIV Infected Persons | Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation. | HIV Infections;AIDS;Lactic Acidosis;Lipodystrophy | Drug: cofactor supplementation (thiamine, riboflavin, L-carnitine) | Queen's University | Ontario HIV Treatment Network | Completed | 18 Years | N/A | Both | 30 | Phase 4 | Canada |
| 3 | NCT00005764 (ClinicalTrials.gov) | May 2000 | 30/5/2000 | A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients | Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) | HIV Infections;Lipodystrophy | Drug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: Lamivudine | Glaxo Wellcome | NULL | Completed | 18 Years | N/A | Both | 100 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-015875-28-IT (EUCTR) | 07/10/2009 | 22/10/2009 | Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora - Role of intestinal microflora in infants with Cystic Fibrosis | Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora - Role of intestinal microflora in infants with Cystic Fibrosis | infants with cystic fibrosis MedDRA version: 9.1;Level: SOC;Classification code 10017947 MedDRA version: 9.1;Classification code 10038738 | INN or Proposed INN: Lactic acid producing organisms | UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 2 | EUCTR2009-011289-27-IT (EUCTR) | 22/04/2009 | 27/04/2009 | Probiotics in Cystic Fibrosis - ND | Probiotics in Cystic Fibrosis - ND | Cystic Fibrosis Patients MedDRA version: 9.1;Level: SOC;Classification code 10017947 | INN or Proposed INN: Lactic acid producing organisms | UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |